Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2026-03-06 @ 12:34 AM
Study NCT ID:
NCT01856218
Status:
COMPLETED
Last Update Posted:
2019-01-04
First Post:
2013-05-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Sponsor:
Ultragenyx Pharmaceutical Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-11
Start Date Type:
None
Primary Completion Date:
2016-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-07
Completion Date Type:
ACTUAL
First Submit Date:
2013-05-08
First Submit QC Date:
None
Study First Post Date:
2013-05-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-11-29
Results First Submit QC Date:
None
Results First Post Date:
2018-01-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2017-05-10
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2018-12-12
Last Update Post Date:
2019-01-04
Last Update Post Date Type:
ACTUAL